Rockley’s unique sensing platform enables continuous health and wellness monitoring of multiple biomarkers, paving the way for the next generation of consumer wearables and medical devices.
 

Transaction will advance the commercial launch of Rockley’s transformational monitoring sensors and the development of commercial opportunities in personal health, medtech and beyond.
 

Transaction values Rockley at a pro forma enterprise value of $1.2 billion.
 

Transaction includes a fully committed $150 million PIPE, with participation from top-tier institutional investors including Senvest Management LLC and UBS O’Connor and participation from Medtronic.
 

Founder Dr. Andrew Rickman, a pioneer in silicon photonics, will remain as CEO and Chairman

Click to download the complete press release.